Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice : a plain language summary of a real-world database study
WHAT ARE THE KEY TAKEAWAYS?: This study used de-identified medical information from the Flatiron Database. This database contains healthcare information on people with cancer treated by doctors in the United States but personal information is removed to maintain privacy. Medical information for people who received certain treatments in routine clinical practice or real-world setting was included in the study. This study showed that in the real-world setting, African-Americans with HR+/HER2- MBC lived longer when receiving palbociclib with an AI than with an AI alone. Also, the study showed that African-Americans treated with palbociclib plus an AI lived longer without their cancer getting worse than those treated with an AI alone.
WHAT WAS THE MAIN CONCLUSION REPORTED BY THE RESEARCHERS?: These results support the use of palbociclib with an AI as a first treatment for African-Americans with HR+/HER2- MBC. Clinical Trial Registration: NCT05361655 (ClinicalTrials.gov).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - (2024) vom: 22. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rugo, Hope S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
African American |
|---|
| Anmerkungen: |
Date Revised 22.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT05361655 Citation Status Publisher |
|---|
| doi: |
10.2217/fon-2023-1079 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370069919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370069919 | ||
| 003 | DE-627 | ||
| 005 | 20240323002411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-1079 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM370069919 | ||
| 035 | |a (NLM)38517416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rugo, Hope S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice |b a plain language summary of a real-world database study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05361655 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a WHAT ARE THE KEY TAKEAWAYS?: This study used de-identified medical information from the Flatiron Database. This database contains healthcare information on people with cancer treated by doctors in the United States but personal information is removed to maintain privacy. Medical information for people who received certain treatments in routine clinical practice or real-world setting was included in the study. This study showed that in the real-world setting, African-Americans with HR+/HER2- MBC lived longer when receiving palbociclib with an AI than with an AI alone. Also, the study showed that African-Americans treated with palbociclib plus an AI lived longer without their cancer getting worse than those treated with an AI alone | ||
| 520 | |a WHAT WAS THE MAIN CONCLUSION REPORTED BY THE RESEARCHERS?: These results support the use of palbociclib with an AI as a first treatment for African-Americans with HR+/HER2- MBC. Clinical Trial Registration: NCT05361655 (ClinicalTrials.gov) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a African American | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a palbociclib | |
| 650 | 4 | |a real-world study | |
| 700 | 1 | |a Liu, Xianchen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a McRoy, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Connie |e verfasserin |4 aut | |
| 700 | 1 | |a Layman, Rachel M |e verfasserin |4 aut | |
| 700 | 1 | |a Tomlin-Harris, Tiah |e verfasserin |4 aut | |
| 700 | 1 | |a Brufsky, Adam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g (2024) vom: 22. März |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-1079 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 03 | ||